Bicocca Open Archive

Logo unimib boa
RUPERTO, NICOLINO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.932
EU - Europa 1.679
NA - Nord America 909
SA - Sud America 347
AF - Africa 52
OC - Oceania 15
Totale 4.934
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 656
HK - Hong Kong 625
RU - Federazione Russa 462
SG - Singapore 449
IT - Italia 290
CN - Cina 251
BR - Brasile 211
DE - Germania 188
TR - Turchia 179
MX - Messico 178
ES - Italia 142
ID - Indonesia 128
AT - Austria 87
FR - Francia 86
IN - India 84
GB - Regno Unito 79
JP - Giappone 72
CO - Colombia 65
CA - Canada 56
NL - Olanda 37
PL - Polonia 35
GR - Grecia 31
FI - Finlandia 26
UA - Ucraina 26
CZ - Repubblica Ceca 24
CH - Svizzera 23
SE - Svezia 21
AR - Argentina 19
MD - Moldavia 18
PH - Filippine 18
DZ - Algeria 16
NO - Norvegia 15
PT - Portogallo 15
SA - Arabia Saudita 15
AU - Australia 14
PE - Perù 14
VN - Vietnam 13
GT - Guatemala 12
HR - Croazia 12
KR - Corea 12
ZA - Sudafrica 12
BE - Belgio 11
CL - Cile 11
EG - Egitto 11
SK - Slovacchia (Repubblica Slovacca) 11
VE - Venezuela 11
IL - Israele 10
TW - Taiwan 10
HU - Ungheria 9
AE - Emirati Arabi Uniti 8
KZ - Kazakistan 8
RO - Romania 8
EC - Ecuador 7
PK - Pakistan 7
TH - Thailandia 7
BO - Bolivia 6
LB - Libano 5
MA - Marocco 5
SI - Slovenia 5
DO - Repubblica Dominicana 4
GE - Georgia 4
IE - Irlanda 4
BY - Bielorussia 3
DK - Danimarca 3
IQ - Iraq 3
LT - Lituania 3
NP - Nepal 3
OM - Oman 3
RS - Serbia 3
UZ - Uzbekistan 3
EE - Estonia 2
IR - Iran 2
KE - Kenya 2
LK - Sri Lanka 2
LY - Libia 2
MN - Mongolia 2
PR - Porto Rico 2
PS - Palestinian Territory 2
PY - Paraguay 2
SN - Senegal 2
SY - Repubblica araba siriana 2
AM - Armenia 1
BD - Bangladesh 1
JO - Giordania 1
KG - Kirghizistan 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
QA - Qatar 1
SV - El Salvador 1
UG - Uganda 1
UY - Uruguay 1
Totale 4.934
Salva come PNG Salva come JPEG
Città #
Hong Kong 609
Singapore 281
Jakarta 98
Milan 82
Istanbul 69
Ashburn 58
Moscow 52
Vienna 43
Nuremberg 42
Rome 41
Bogotá 36
Ankara 32
Madrid 27
Shanghai 26
Mexico City 25
São Paulo 25
Paris 24
Guadalajara 22
Xi'an 22
Tokyo 20
Frankfurt am Main 19
Chisinau 18
Guangzhou 18
Beijing 17
Helsinki 17
Chicago 15
London 15
Seattle 15
Athens 14
Barcelona 14
Goiânia 14
Heidelberg 14
Manchester 14
Palermo 14
Valencia 14
Chongqing 13
Pereira 13
Chengdu 12
Genoa 12
Guatemala City 12
Lisbon 12
Naples 12
Silver Spring 12
Zagreb 12
Brno 11
Orlando 11
Puebla City 11
Rio de Janeiro 11
Riyadh 11
Atlanta 10
Belo Horizonte 10
Coyoacán 10
Langfang 10
Lima 10
Los Angeles 10
Padova 10
Prague 10
Santiago 10
Toronto 10
Bologna 9
Denver 9
Hyderabad 9
Lipa City 9
Pune 9
Shenyang 9
Amsterdam 8
Birmingham 8
Brasília 8
Buenos Aires 8
Cixi 8
Hangzhou 8
León 8
Melbourne 8
Monterrey 8
Mumbai 8
Málaga 8
New York 8
Oslo 8
St Petersburg 8
Algiers 7
Bangkok 7
Bury 7
Cincinnati 7
Dublin 7
Gustavo Adolfo Madero 7
Krakow 7
Medellín 7
Oaxaca City 7
Ottawa 7
Taipei 7
Tel Aviv 7
Adana 6
Antalya 6
Astana 6
Benito Juarez 6
Bucharest 6
Cardiff 6
Cuauhtémoc 6
Düsseldorf 6
Florence 6
Totale 2.435
Salva come PNG Salva come JPEG
Nome #
Juvenile idiopathic arthritis 920
Classification criteria for autoinflammatory recurrent fevers 489
The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist 259
Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial 257
Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial 217
Do the Provisional Paediatric Rheumatology International Trials Organisation Enthesitis/Spondylitis-Related Juvenile Idiopathic Arthritis Criteria Capture Youth With Axial Spondyloarthritis? 108
Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis 104
Abatacept: A Review of the Treatment of Polyarticular-Course Juvenile Idiopathic Arthritis 66
Factors for Consideration by Pediatric Rheumatologists When Scoring the Physician Global Assessment of Disease Activity in Juvenile Idiopathic Arthritis: First Step Toward an Internal Consensus 62
Clinical characteristics and genetic analyses of 187 patients with undefined autoinflammatory diseases 51
Defining criteria for disease activity states in juvenile dermatomyositis based on the Juvenile Dermatomyositis Activity Index 48
Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis 42
Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open-Label, Active-Treatment Extension Study 38
Efficacy and safety of TNF inhibitors in the treatment of juvenile idiopathic arthritis: a systematic literature review 37
Ten-year safety and clinical benefit from open-label etanercept treatment in children and young adults with juvenile idiopathic arthritis 36
Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in Childhood Polyarteritis Nodosa: An Open-Label, Randomized, Bayesian Noninferiority Trial 36
Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus 35
Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: Preliminary results of an open-label, long-term extension study 33
Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee 32
Intravenous Golimumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis: Long-Term Extension of an Open-Label Phase III Study 31
Response to: 'Do we need the PFAPA syndrome in adults with non-monogenic periodic fevers?' by Fayand et al 30
Patient-Reported Outcomes Among Patients Ages Two to Seventeen Years With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Subcutaneous Abatacept: Two-Year Results From an International Phase III Study 29
Anakinra in Patients With Systemic Juvenile Idiopathic Arthritis: Long-term Safety From the Pharmachild Registry 29
Monitoring of Adverse Events and Safety in Autoinflammatory Diseases: Real-Life Data from the Eurofever Registry 29
Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: A randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial 29
Summary of Research: Ten-Year Safety and Clinical Benefit from Open-Label Etanercept Treatment in Children and Young Adults with Juvenile Idiopathic Arthritis 29
Clinical features, treatment and outcomes of Italian children with enthesitis-related arthritis and juvenile psoriatic arthritis: a cross-sectional cohort study 29
Safety and effectiveness of abatacept in juvenile idiopathic arthritis: Results from the PRINTO/PRCSG registry 28
S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis 27
Long-term efficacy and safety of subcutaneous tocilizumab in clinical trials of polyarticular or systemic juvenile idiopathic arthritis 27
Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis 27
Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial 27
Thrombotic manifestations in pediatric Behcet syndrome: A multicenter comparative study from the EUROFEVER registry 26
Maintenance of antibody response to diphtheria/tetanus vaccine in patients aged 2-5 years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept 25
Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison 25
null 24
Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis 24
Juvenile idiopathic arthritis patients with positive family history of autoimmune thyroid disease might benefit from serological screening: analysis of the international Pharmachild registry 24
Development and testing of reduced versions of the MMT-8 in juvenile dermatomyositis 24
Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate 24
Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven-Year Interim Results 24
Drivers of non-zero physician global scores during periods of inactive disease in juvenile idiopathic arthritis 24
Breaking down the fences among registries on autoinflammatory diseases: the E-Merge project 23
Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial 22
Real-world comparison of the effects of etanercept and adalimumab on well-being in non-systemic juvenile idiopathic arthritis: a propensity score matched cohort study 22
"To Randomize, or Not to Randomize, That is the Question" 22
Increased incidence of inflammatory bowel disease on etanercept in juvenile idiopathic arthritis regardless of concomitant methotrexate use 22
Tapering Canakinumab Monotherapy in Patients with Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results from an Open‐label, Randomized Phase IIIb/IV Study 22
Approaches to SARS-CoV-2 and other vaccinations in children with a history of multisystem inflammatory syndrome (MIS-C): An international survey 22
Abatacept as Monotherapy and in Combination With Methotrexate in Patients With Juvenile Idiopathic Arthritis: Analysis of 2 Phase III Trials 22
Clinical trials in children and adolescents with systemic lupus erythematosus: Methodological aspects, regulatory landscape and future opportunities 21
Performance of the 2016 ACR-EULAR myositis response criteria in adult dermatomyositis/polymyositis therapeutic trials and consensus profiles 21
Validation of the PEDiatric Behçet’s Disease classification criteria: an evidence-based approach 21
Long-Term Maintenance of Clinical Responses by Individual Patients With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Abatacept 21
Development and External Validation of a Model Predicting New-Onset Chronic Uveitis at Different Disease Durations in Juvenile Idiopathic Arthritis 21
The HyperPed-COVID international registry: Impact of age of onset, disease presentation and geographical distribution on the final outcome of MIS-C 21
Clinical insights into heterogeneity of rheumatoid factor negative polyarticular juvenile idiopathic arthritis across the world 21
Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: Post hoc radiographic analysis from two randomized controlled trials 21
Classification Criteria for Axial Disease in Youth With Juvenile Spondyloarthritis 20
Burden of comorbid conditions in children and young people with juvenile idiopathic arthritis: a collaborative analysis of 3 JIA registries 20
Prevalence of familial autoimmune diseases in juvenile idiopathic arthritis: results from the international Pharmachild registry 20
Improving clinical paediatric research and learning from COVID-19: recommendations by the Conect4Children expert advice group 20
TNFRSF1A-pR92Q variant identifies a subset of patients more similar to systemic undifferentiated recurrent fever than TNF receptor-associated periodic syndrome 19
Absence of Association Between Abatacept Exposure and Initial Infection in Patients With Juvenile Idiopathic Arthritis 19
Validity and Reliability of Four Parent/Patient-Reported Outcome Measures for Juvenile Idiopathic Arthritis Remote Monitoring 19
The Romanian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 19
Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis 19
Looking for the best strategy to treat children with new onset juvenile idiopathic arthritis: presentation of the "comparison of STep-up and step-down therapeutic strategies in childhood ARthritiS" (STARS) trial 19
Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever Registry 19
Towards European harmonisation of healthcare for patients with rare immune disorders: outcome from the ERN RITA registries survey 18
Corrigendum to The impact of the Eurofever criteria and the new InFevers MEFV classification in real life: Results from a large international FMF cohort (Seminars in Arthritis and Rheumatism (2022) 52, (S0049017222000087), (10.1016/j.semarthrit.2022.151957)): <[ Seminars in Arthritis and Rheumatism Volume 52, 151957]> 18
Tofacitinib for juvenile idiopathic arthritis – Authors' reply 18
Correction to: Improving clinical paediatric research and learning from COVID-19: recommendations by the Conect4Children expert advice group (Pediatric Research, (2022), 91, 5, (1069-1077), 10.1038/s41390-021-01587-3) 18
Neutropenia During Tocilizumab Treatment Is Not Associated with Infection Risk in Systemic or Polyarticular-course Juvenile Idiopathic Arthritis 18
Proposed Response Parameters for Twelve-Month Drug Trial in Juvenile Systemic Sclerosis: Results of the Hamburg International Consensus Meetings 18
A clinical prediction model for estimating the risk of developing uveitis in patients with juvenile idiopathic arthritis 18
Paediatric rheumatologists do not score the physician's global assessment of juvenile idiopathic arthritis disease activity in the same way 18
Development and validation of a composite disease activity score for measurement of muscle and skin involvement in juvenile dermatomyositis 18
The Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 18
American College of Rheumatology Provisional Criteria for Clinically Relevant Improvement in Children and Adolescents With Childhood-Onset Systemic Lupus Erythematosus 18
Performance of the 2016 ACR-EULAR myositis response criteria in juvenile dermatomyositis therapeutic trials and consensus profiles 17
Growth and Puberty in Juvenile Dermatomyositis: A Longitudinal Cohort Study 17
The Egyptian Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 17
Biomarker Changes in Response to Tofacitinib Treatment in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis 17
Clinical features, treatment and outcome of pediatric patients with severe cutaneous manifestations in IgA vasculitis: Multicenter international study 17
Treatment of juvenile idiopathic arthritis: what's new? 17
Establishing an Updated Core Domain Set for Studies in Juvenile Idiopathic Arthritis: A Report from the OMERACT 2018 JIA Workshop 17
Some clarifications on the new classification criteria for recurrent fevers 16
Definition and Validation of the American College of Rheumatology 2021 Juvenile Arthritis Disease Activity Score Cutoffs for Disease Activity States in Juvenile Idiopathic Arthritis 16
PROMs for juvenile idiopathic arthritis 16
Juvenile arthritis management in less resourced countries (JAMLess): consensus recommendations from the Cradle of Humankind 16
Transcriptional Profiling of Tofacitinib Treatment in Juvenile Idiopathic Arthritis: Implications for Treatment Response Prediction 16
Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study 16
Outcome Scores in Pediatric Rheumatology 16
Reduction in the utilization of prednisone or methotrexate in Canadian claims data following initiation of etanercept in pediatric patients with juvenile idiopathic arthritis 15
The Latvian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 15
The impact of the Eurofever criteria and the new InFevers MEFV classification in real life: Results from a large international FMF cohort 15
The PRINTO evidence-based proposal for glucocorticoids tapering/discontinuation in new onset juvenile dermatomyositis patients 15
Determinants of Discordance Between Criteria for Inactive Disease and Low Disease Activity in Juvenile Idiopathic Arthritis 15
2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects 15
Totale 4.562
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.932
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.932
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2024/20255.985 0 0 0 0 605 129 1.200 822 1.717 1.474 38 0
Totale 5.985